Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 3481578, 9 pages
http://dx.doi.org/10.1155/2016/3481578
Research Article

Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer

1III. Medizinische Klinik, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
2Stratifyer Molecular Pathology GmbH, 50935 Köln, Germany
3Pathologisches Institut, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
4Chirurgische Klinik, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
5Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
6Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, 07747 Jena, Germany
7Klinik für Urologie, Universitätsmedizin Mannheim, 68167 Mannheim, Germany

Received 27 May 2016; Accepted 19 July 2016

Academic Editor: Haruhiko Sugimura

Copyright © 2016 Melanie Kripp et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. No predictive or prognostic biomarker is available for patients with locally advanced rectal cancer (LARC) undergoing perioperative chemoradiotherapy (CRT). Members of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases EGFR (HER1, ERBB1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4) are therapeutic targets in several cancers. The analysis was performed to assess expression levels and study the potential prognostic impact for disease-free and overall survival in patients with LARC. Patients and Methods. ERBB1–4 mRNA expression and tumor proliferation using Ki-67 (MKI67) mRNA were evaluated using RT-quantitative PCR in paraffin-embedded tumor samples from 86 patients (median age: 63) treated with capecitabine or 5-fluorouracil-based CRT within a phase 3 clinical trial. Results. A positive correlation of HER4 and HER2, HER3 and HER2, and HER4 and HER3 with each other was observed. Patients with high mRNA expression of ERBB1 (EGFR, HER1) had significantly increased risk for recurrence and death. Patients with high mRNA expression of MKI67 had reduced risk for relapse. Conclusion. This analysis suggests a prognostic impact of both ERBB1 and MKi67 mRNA expression in LARC patients treated with capecitabine or fluorouracil-based chemoradiotherapy.